Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Shares Outstanding (Weighted Average): 2017-2024

Historic Shares Outstanding (Weighted Average) for Mereo BioPharma Group (MREO) over the last 8 years, with Dec 2024 value amounting to $795.0 million.

  • Mereo BioPharma Group's Shares Outstanding (Weighted Average) rose 3.41% to $795.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $795.5 million, marking a year-over-year increase of 3.41%. This contributed to the annual value of $795.0 million for FY2024, which is 13.35% up from last year.
  • Latest data reveals that Mereo BioPharma Group reported Shares Outstanding (Weighted Average) of $795.0 million as of FY2024, which was up 13.35% from $701.4 million recorded in FY2023.
  • Mereo BioPharma Group's 5-year Shares Outstanding (Weighted Average) high stood at $795.0 million for FY2024, and its period low was $339.0 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $693.8 million, with a median of $701.4 million in 2023.
  • Data for Mereo BioPharma Group's Shares Outstanding (Weighted Average) shows a peak YoY spiked of 376.43% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Shares Outstanding (Weighted Average) stood at $339.0 million in 2020, then surged by 72.56% to $584.9 million in 2021, then remained steady at $584.9 million in 2022, then increased by 19.91% to $701.4 million in 2023, then rose by 13.35% to $795.0 million in 2024.